ArticleFEBS open bio2025
High LRIG1 expression predicts lymph node metastasis in patients with uterine cervical cancer.
Article in FEBS open bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Fifteen percent of patients with preoperative stage IA2-IB1 uterine cervical cancer are diagnosed with lymph node metastasis (LNM) following surgery. They must be treated with both surgery and radiotherapy, a combination associated with severe side effects. Since current diagnostic methods have limitations, biomarkers are urgently needed to improve staging. Leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) is a regulator of growth factor signaling and a prognostic factor in cervical cancer. This study investigates whether LRIG1 expression could predict LNM in cervical cancer. Sixty-seven patients were included: 31 without LNM and 36 with LNM. Tumor blocks were retrieved, and clinical data were collected. Immunohistochemical analysis of LRIG1 expression was performed, and LRIG1 immunoreactivity was correlated with lymph node status and clinicopathological prognostic factors, such as human papillomavirus status and smoking status. High LRIG1 expression (> 25% positive cells) was significantly associated with an increased risk of LNM (odds ratio 9.49, 95% CI: 1.80-50.05, P = 0.008, adjusted for age, smoking status, and BMI), suggesting the potential of LRIG1 as a biomarker. Larger, multicenter studies are needed to validate our results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.